SERA
Sera Prognostics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.33
P/S
947.33
EV/EBITDA
-2.11
DCF Value
$-0.01
FCF Yield
-34.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-102.5%
Operating Margin
-45066.7%
Net Margin
-39417.3%
ROE
-37.5%
ROA
-31.6%
ROIC
-47.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $10.0K | $-7.9M | $-0.16 |
| FY 2025 | $81.0K | $-31.9M | $-0.67 |
| Q3 2025 | $16.0K | $-7.8M | $-0.16 |
| Q2 2025 | $17.0K | $-8.0M | $-0.16 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.06
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.